Alfuzosin 10 mg once daily in the management of acute urinary retention: Results of a double-blind placebo-controlled study

Urology

Volumn 65, Issue 1, 2005, Pages 83-89

  McNeill, S A ^a   Hargreave, T B ^b   Roehrborn, Claus G ^c  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; PLACEBO;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CATHETERIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REDUCTION; RELAPSE; RISK FACTOR; SURVIVAL RATE; URINE RETENTION; URINE VOLUME;

ACUTE DISEASE; ADRENERGIC ALPHA-ANTAGONISTS; AGED; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EMERGENCIES; HUMANS; LIFE TABLES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; QUINAZOLINES; RECURRENCE; URINARY CATHETERIZATION; URINARY RETENTION;

EID: 12844253013     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.07.042     Document Type: Article

References (21)

1. S.J. Jacobsen, D.J. Jacobson, C.J. Girman Natural history of prostatism risk factors for acute urinary retention J Urol 158 1997 481 487
2. M. Emberton, K. Anson Acute urinary retention in men an age old problem BMJ 318 1999 921 925
3. National Prostatectomy Audit Steering Group R. Pickard, M. Emberton, D.E. Neal The management of men with acute urinary retention Br J Urol 81 1998 712 720
4. M. Taube, H. Gajraj Trial without catheter following acute retention of urine BJU Int 63 1989 180 182
5. K.J. Hastie, A.J. Dickinson, R. Ahmad Acute retention of urine is trial without catheter justified? J R Coll Surg Edinb 35 1990 225 227
6. S.A. McNeill, P.D. Daruwala, I.D. Mitchell Sustained-release alfuzosin and trial without catheter after acute urinary retention a prospective, placebo-controlled BJU Int 84 1999 622 627
7. AUA Practice Guidelines Committee AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendation J Urol 170 2003 530 547
8. C. Chatelain, L. Denis, K.T. Foo Recommendations of the International Consensus Committee C. Chatelain L. Denis K.T. Foo Proceedings of the Fifth International Consultation on Benign Prostatic Hyperplasia (BPH), Paris, June 25-28, 2003 2003 Scientific Communications International Jersey 519 534
9. L. Breum, P. Klarskov, L.K. Munck Significance of acute urinary retention due to intravesical obstruction Scand J Urol Nephrol 16 1982 21 24
10. P. Klarskov, J.T. Andersen, C.F. Asmussen Symptoms and signs predictive of the voiding pattern after acute urinary retention in men Scand J Urol Nephrol 21 1987 23 28
11. V. Kumar, C. Marr, A. Bhuvangiri A prospective study of conservatively managed acute urinary retention prostate size matters BJU Int 86 2000 816 819
12. S.A. McNeill, T.B. Hargreave, H. Gallagher Long-term follow-up following presentation with a first episode of acute urinary retention (abstract) J Urol 163 suppl 2000 307
13. C.C. Schulman Long-term aspects of medical treatment of BPH Eur Urol 40 suppl 3 2001 8 12
14. P.S.F. Chan, W.S. Wong, L.W. Chan Can terazosin (alpha-blocker) relieve acute urinary retention and obviate the need for an indwelling urethral catheter (abstract)? Br J Urol 77 suppl 1 1996 7
15. E. Bowden, S. Hall, S.J. Folly Tamsulosin in the treatment of urinary retention a prospective, placebo-controlled trial (abstract) BJU Int 88 suppl 1 2001 77
16. M. Lucas, T.P. Stephenson, V. Nargund Tamsulosin reduces the need for recatheterisation following an episode of acute urinary retention in elderly benign prostatic hyperplasia patients (abstract) J Urol 167 suppl 2002 266
17. C.G. Roehrborn, P. van Kerrebroeck, J. Nordling Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia a pooled analysis of three double-blind, placebo-controlled studies BJU Int 92 2003 257 261
18. Members of the ALFAUR Study Group S.A. McNeill, T.B. Hargreave Alfuzosin 10 mg once daily facilitates return to voiding in patients with acute urinary retention J Urol 171 2004 2316 2320
19. W.K. Mebust, H.L. Holtgrewe, A.T.K. Cockett Transurethral prostatectomy: immediate and post-operative complications. A co-operative study of 13 participating institutions evaluation of 3,885 patients J Urol 141 1989 243 247
20. D.D. Cravens, S. Zweig Urinary catheter management Am Fam Physician 2 2000 369 376
21. C.G. Roehrborn, J.D. McConnell, M. Lieber Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia Urology 53 1999 473 480